The American Medical Association has issued a statement urging federal regulators to maintain rigorous testing standards for botanical drugs like cannabis and kratom, cautioning that political and commercial pressures should not override established scientific protocols.
The nation's largest physician organization is pushing for a "special schedule" that would facilitate research on plant-based medicines while preserving FDA approval requirements. The position comes as state-level cannabis legalization expands and interest in alternative botanicals grows among consumers and lawmakers alike.
"We need to ensure that botanical drug products meet the same safety and efficacy standards as other pharmaceuticals," the AMA stated in its policy recommendation. The group emphasized that "known and widely accepted scientific and clinical standards" must apply regardless of a substance's cultural acceptance or political momentum.
Research vs. Access
The AMA's stance reflects ongoing tension in drug policy between expanding research access and maintaining regulatory guardrails. Cannabis remains Schedule I under federal law despite 38 states legalizing medical use and 24 allowing adult recreational consumption. That classification creates barriers for researchers seeking to study potential therapeutic applications.
Research indicates that current scheduling creates a catch-22: scientists need more data to support rescheduling, but the Schedule I designation makes obtaining that data difficult. The AMA's proposed special schedule could address this gap by creating a pathway specifically designed for botanical research.
The medical group's concerns extend beyond cannabis to include kratom, a Southeast Asian plant that some users report helps with pain and opioid withdrawal. The FDA has not approved kratom for medical use and has warned about potential risks, though the substance remains legal in most states.
Industry Implications
The pharmaceutical industry has long grappled with how to standardize botanical medicines, which contain multiple active compounds rather than single isolated molecules. Cannabis products, for instance, include hundreds of cannabinoids and terpenes that may interact in ways not yet fully understood.
Clinical evidence shows significant variability in botanical product composition even within the same plant species, depending on growing conditions, harvest timing, and processing methods. This complexity makes traditional drug approval processes challenging to apply.
Several pharmaceutical companies have successfully navigated FDA approval for cannabis-derived medications, including GW Pharmaceuticals' Epidiolex for epilepsy. But these products use isolated compounds or standardized extracts, not whole-plant preparations.
What's Next
The AMA's recommendations will likely influence ongoing discussions about cannabis rescheduling and botanical drug regulation. The DEA is currently reviewing a Department of Health and Human Services recommendation to move cannabis to Schedule III, which would acknowledge medical value while maintaining federal controls.
Industry observers note that any special schedule for botanical research would need congressional action, not just regulatory changes. The proposal adds another dimension to cannabis policy debates that have focused primarily on criminal justice reform and taxation issues.
The medical association's statement also signals that healthcare providers want more robust clinical data before fully embracing botanical medicines. That position may frustrate patient advocates who argue that existing evidence and clinical experience already support wider medical use, particularly for cannabis.
Regulatory clarity around botanical drugs could reshape both the pharmaceutical and cannabis industries, potentially opening new research funding while imposing stricter manufacturing and testing requirements on existing products.
This article is based on original reporting by www.marijuanamoment.net.
